← 返回

NLRX1 作为食管鳞状细胞癌预后因素的生物信息学分析与实验验证

英文原题:Bioinformatics analysis and experimental verification of NLRX1 as a prognostic factor for esophageal squamous cell carcinoma.

查看英文原题

Bioinformatics analysis and experimental verification of NLRX1 as a prognostic factor for esophageal squamous cell carcinoma.

PubMed 2024/04/11(内容时间) Oncol Lett Q3 · IF 2.1(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

中文摘要

核苷酸结合寡聚化结构域样受体X1(NLRX1)是NLR家族的一员,与炎症、自噬、免疫、代谢和线粒体调节的生理和病理过程相关,并已被证实在多种肿瘤类型中具有促肿瘤或抗肿瘤作用。

然而,NLRX1在食管鳞状细胞癌(ESCC)中的生物学功能仍不清楚。在本研究中,采用生物信息学方法检测了NLRX1在mRNA水平上的差异表达。进行了总生存期、临床相关性、受试者工作特征曲线、Cox回归、共表达、富集、免疫浸润和药物敏感性分析。构建了列线图和校准曲线。通过免疫组织化学和western blotting检测了蛋白表达水平的变化。通过CCK-8实验评估了NLRX1对i)细胞增殖的影响;通过伤口愈合实验检测了ii)迁移;通过Transwell实验评估了iii)迁移和侵袭;通过Annexin V/PI染色和流式细胞术评估了iv)凋亡。

结果显示,与正常癌旁组织相比,NLRX1在ESCC中低表达,且NLRX1低表达患者的生存时间较短。NLRX1是ESCC的独立预后因素,并与肿瘤分级相关。低NLRX1组患者的活化NK 细胞、单核细胞和M0巨噬细胞浸润减少,且这些免疫细胞浸润水平与NLRX1表达呈正相关。敲低NLRX1促进KYSE450细胞增殖,而过表达NLRX1抑制ECA109细胞增殖。NLRX1负向调控ESCC中的PI3K/AKT信号通路。这些发现表明,NLRX1通过多种机制抑制ESCC中的肿瘤生长,这为研究ESCC的病因和进展以及寻找更有效的治疗方法提供了新的见解。

展开英文摘要原文

Nucleotide binding and oligomeric domain-like receptor X1 (NLRX1), a member of the NLR family, is associated with the physiological and pathological processes of inflammation, autophagy, immunity, metabolism and mitochondrial regulation, and has been demonstrated to have pro- or antitumor effects in various tumor types.

However, the biological function of NLRX1 in esophageal squamous cell carcinoma (ESCC) has remained elusive. In the present study, by using bioinformatics methods, the differential expression of NLRX1 at the mRNA level was examined.

Overall survival, clinical correlation, receiver operating characteristic curve, Cox regression, co-expression, enrichment, immune infiltration and drug sensitivity analyses were carried out. A nomogram and a calibration curve were constructed. Changes in protein expression levels were investigated by immunohistochemistry and western blotting. The impact of NLRX1 on i) cell proliferation was evaluated by Cell Counting Kit-8 assays; ii) migration was examined by wound-healing assays; iii) migration and invasion were evaluated by Transwell assays; and iv) apoptosis was assessed by Annexin V/PI staining and flow cytometry.

The results revealed that, compared to normal adjacent tissue, NLRX1 was lowly expressed in ESCC, and patients with low NLRX1 expression had a shorter survival time. NLRX1 was an independent prognostic factor for ESCC and was associated with tumor grading.

Patients in the low-NLRX1 group showed a decrease in the infiltration of activated natural killer cells, monocytes and M0 macrophages, and these immune-cell infiltration levels were positively correlated with NLRX1 expression. Knocking down NLRX1 promoted the proliferation of KYSE450 cells, while overexpression of NLRX1 inhibited the proliferation of ECA109 cells. NLRX1 negatively regulated the PI3K/AKT signaling pathway in ESCC.

These findings indicate that, through several mechanisms, NLRX1 suppresses tumor growth in ESCC, which offers new insight for investigating the causes and progression of ESCC, as well as for identifying more efficient therapeutic approaches.

论文信息

作者
Zhou L、Gan L、Sun C、Chu A、Yang M、Liu Z
单位
Tumor Radiotherapy Department, The Second Affiliated Hospital, Zhengzhou University, Zhengzhou, Henan 450000, P.R. China.China
期刊
Oncology letters2024 Jun
原文标识
PubMed 38659420 · DOI 10.3892/ol.2024.14397